102 related articles for article (PubMed ID: 17483377)
1. B cell depletion in Graves' disease: the right answer to the wrong question?
Smith TJ
J Clin Endocrinol Metab; 2007 May; 92(5):1620-2. PubMed ID: 17483377
[No Abstract] [Full Text] [Related]
2. B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study.
El Fassi D; Nielsen CH; Bonnema SJ; Hasselbalch HC; Hegedüs L
J Clin Endocrinol Metab; 2007 May; 92(5):1769-72. PubMed ID: 17284622
[TBL] [Abstract][Full Text] [Related]
3. Treatment-resistant severe, active Graves' ophthalmopathy successfully treated with B lymphocyte depletion.
El Fassi D; Nielsen CH; Hasselbalch HC; Hegedüs L
Thyroid; 2006 Jul; 16(7):709-10. PubMed ID: 16889501
[No Abstract] [Full Text] [Related]
4. B-cell depletion with rituximab in the treatment of autoimmune diseases. Graves' ophthalmopathy the latest addition to an expanding family.
Nielsen CH; El Fassi D; Hasselbalch HC; Bendtzen K; Hegedüs L
Expert Opin Biol Ther; 2007 Jul; 7(7):1061-78. PubMed ID: 17665994
[TBL] [Abstract][Full Text] [Related]
5. Evidence of orbital B and T cell depletion after rituximab therapy in Graves' ophthalmopathy.
Nielsen JF; El Fassi D; Nielsen CH; Hegedüs L; Lauer SA; Silkiss RZ; Prause JU
Acta Ophthalmol; 2009 Nov; 87(8):927-9. PubMed ID: 19785644
[No Abstract] [Full Text] [Related]
6. Hypoglycemia due to insulin binding antibodies in a patient with insulin-treated type 2 diabetes and Graves' disease.
Wang X; Xu XL; Zhao XL; Ma XW; Yu H; Gong H; Zhang SR; Chen FL
Endocrine; 2013 Feb; 43(1):236-7. PubMed ID: 22886314
[No Abstract] [Full Text] [Related]
7. Methimazole treatment in Graves' disease: behaviour of CD5+B lymphocytes and regulatory T cell subsets.
Paggi A; Amoroso A; Ferri GM; Mariotti A; Pellegrino C; Afeltra A
Eur Rev Med Pharmacol Sci; 1998; 2(1):11-9. PubMed ID: 9825565
[TBL] [Abstract][Full Text] [Related]
8. Changes of serum cytokines in hyperthyroid Graves' disease patients at diagnosis and during methimazole treatment.
Pedro AB; Romaldini JH; Takei K
Neuroimmunomodulation; 2011; 18(1):45-51. PubMed ID: 20628263
[TBL] [Abstract][Full Text] [Related]
9. [Novel treatment of Graves' disease using the B-lymphocyte depleting agent rituximab].
Nielsen CH; El Fassi D; Hegedüs L
Ugeskr Laeger; 2008 Jun; 170(24):2131-4. PubMed ID: 18565295
[TBL] [Abstract][Full Text] [Related]
10. Serum BAFF concentrations in patients with Graves' disease and orbitopathy before and after immunosuppressive therapy.
Vannucchi G; Covelli D; Currò N; Dazzi D; Maffini A; Campi I; Bonara P; Guastella C; Pignataro L; Ratiglia R; Beck-Peccoz P; Salvi M
J Clin Endocrinol Metab; 2012 May; 97(5):E755-9. PubMed ID: 22399512
[TBL] [Abstract][Full Text] [Related]
11. [Assessment of early immunosuppressive therapy in the prevention of complications of Graves' disease].
Huszno B; Trofimiuk M; Gołkowski F; Plinta T; Szybiński Z
Przegl Lek; 2004; 61(8):868-71. PubMed ID: 15789920
[TBL] [Abstract][Full Text] [Related]
12. Serum levels of the interferon-gamma-inducible alpha chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy.
Antonelli A; Fallahi P; Rotondi M; Ferrari SM; Serio M; Miccoli P
Br J Surg; 2006 Oct; 93(10):1226-31. PubMed ID: 16838393
[TBL] [Abstract][Full Text] [Related]
13. Preventing Graves' ophthalmopathy.
Wiersinga WM
N Engl J Med; 1998 Jan; 338(2):121-2. PubMed ID: 9420345
[No Abstract] [Full Text] [Related]
14. B-cell depletion with rituximab-a targeted therapy for Graves' disease and autoimmune thyroiditis.
Hasselbalch HC
Immunol Lett; 2003 Jul; 88(1):85-6. PubMed ID: 12853167
[No Abstract] [Full Text] [Related]
15. Antithyroid drug-induced immunomodulation in Graves' disease patients.
Lechpammer M; Lukac J; Lechpammer S; Kusić Z
Acta Med Croatica; 2002; 56(1):21-6. PubMed ID: 12455450
[TBL] [Abstract][Full Text] [Related]
16. Evidence of intrathyroidal B-lymphocyte depletion after rituximab therapy in a patient with Graves' disease.
El Fassi D; Clemmensen O; Nielsen CH; Silkiss RZ; Hegedüs L
J Clin Endocrinol Metab; 2007 Oct; 92(10):3762-3. PubMed ID: 17933978
[No Abstract] [Full Text] [Related]
17. Unusual problems in the management of hyperthyroid Graves' disease.
Steenkamp DW; Junqueira A; Braverman LE
Endocr Pract; 2013; 19(1):162-5. PubMed ID: 23435045
[No Abstract] [Full Text] [Related]
18. The distribution of the major peripheral blood T, B and NK cell subsets does not predict the clinical outcome of Graves' disease patients after methimazole therapy.
Corrales JJ; López A; Ciudad J; Orfao A
J Biol Regul Homeost Agents; 2000; 14(3):193-9. PubMed ID: 11037052
[TBL] [Abstract][Full Text] [Related]
19. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy.
Bartalena L; Marcocci C; Bogazzi F; Manetti L; Tanda ML; Dell'Unto E; Bruno-Bossio G; Nardi M; Bartolomei MP; Lepri A; Rossi G; Martino E; Pinchera A
N Engl J Med; 1998 Jan; 338(2):73-8. PubMed ID: 9420337
[TBL] [Abstract][Full Text] [Related]
20. Serum antibodies to collagen XIII: a further good marker of active Graves' ophthalmopathy.
De Bellis A; Sansone D; Coronella C; Conte M; Iorio S; Perrino S; Battaglia M; Bellastella G; Wall JR; Bellastella A; Bizzarro A
Clin Endocrinol (Oxf); 2005 Jan; 62(1):24-9. PubMed ID: 15638866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
